Since the 1980s, researchers have investigated whether it’s possible to take immune cells from a tumor, multiply them in the lab, and put them back into the body better equipped to fight cancer.
In February, decades of research became a reality when the Food and Drug Administration approved lifileucel, the first treatment to extract, multiply and reinsert cells called tumor-infiltrating lymphocytes to fight cancer.
The treatment is used for patients with melanoma who have exhausted all other treatment options. About 100,000 people are diagnosed with melanoma, the most dangerous form of skin cancer, in the U.S. every year. About 8,290 people are expected to die of melanoma this year, according to the American Cancer Society — about 5,430 men and 2,860 women.
At West Penn Hospital, doctors have treated about five melanoma patients since the drug was approved in February. “So far, we have been very pleased with the results,” said Yazan Samhouri, lead physician of AHN’s cellular therapy program. One patient in particular showed a 90% reduction in combined cancer masses at the six-week mark after treatment. “We were really pleased seeing this deep and robust and quick effect of treatment for these kinds of tumors,” said Samhouri. He expects that AHN will be able to treat 10 to 15 patients per year with lifileucel, which is sold under the brand name Amtagvi.
UPMC participated in the clinical trial that led to the FDA approval of lifileucel and has treated about 10 patients since the drug was approved this year, with plans to treat two more before the year is over. John Kirkwood, co-leader of the Melanoma and Skin Cancer Program at the UPMC Hillman Cancer Center, remembers seeing some remarkable results in Pittsburgh patients during the trial, which began about eight years ago.
“They had disease in their brain, their heart, their lungs, and then they had zero — a complete response, no disease left after one treatment,” he said, describing the effect of the treatment during the clinical trial. “It was truly shocking and inspired.”
Read More
In the more than 70 patients who were treated with the drug nationwide during the clinical trial, almost one-third had some reduction in the size of their tumors. In a few patients, the tumors — which had previously been resistant to treatment — disappeared entirely.
Of those whose cancer responded to lifileucel, 40% had no further cancer progression one year after receiving the treatment.

Both UPMC and AHN said that their early results so far are in line with the success seen in the clinical trials — which is particularly encouraging given that before lifileucel was approved, these patients would have been out of options.
“There was no approved treatment for these patients,” said Samhouri. “This treatment provided a novel immune therapy for a huge unmet need in treating melanoma patients. It’s saving lives.”
Patients spend several weeks in the hospital to receive treatment with lifileucel. First, a piece of their tumor is extracted and sent to the lab, where immune cells are isolated and mixed with an immune-boosting drug, IL-2, to help them multiply. The patient is then given six doses of chemotherapy to prepare the immune system better to receive the immune cells when they are infused back into the body.
After the cells are infused back into the patient’s body, they are also given doses of IL-2 to help their immune system respond.
“It takes a whole month but once they are done, they are done,” said Kirkwood, who is also a professor of medicine at Pitt. “If they have a benefit, as a couple of my patients have had, we don’t expect that we will need to treat them with anything else — it’s a one and done.”
While there is always a risk of infection, the side effects of the actual treatment seem minimal, said Samhouri, with most of the negative effects coming from the chemotherapy received in preparation for treatment, he said.
At UPMC, Kirkwood has been doing research into similar treatments since the 1990s. He credits Iovance Biotherapeutics, the drug company manufacturing Amtagvi, for stepping in to take on the role of harvesting and growing the immune cells, making the research that was taking place in various forms at numerous academic centers into a viable treatment. He hopes that the treatment can persist despite its cost, which is currently about $500,000 per patient.
Numerous clinical trials are taking place in hopes of both improving the effectiveness of using tumor-infiltrating lymphocytes to fight melanoma, as well as expand the use to other solid-tumor cancers, such as breast cancer, lung cancer and colon cancer.
“There’s no reason it shouldn’t be applicable to many other solid tumors,” said Kirkwood.
And if so, the implications for cancer treatment as a whole are significant.
“It’s going to change how we think of cancer medicine,” said Samhouri. “It’s the future of how we treat cancers.”

Kirkwood will lead a clinical trial at Pitt and UPMC in the next few months attempting to further improve melanoma treatment using tumor-infiltrating lymphocytes. For Kirkwood, it’s a far cry from when he began in the field in the 1970s. He remembers his mentor at Harvard at the time calling melanoma “the tumor that gave cancer a bad name.”
Even 15 years ago, when melanoma patients came to his clinic, he didn’t have much to offer them in terms of treatment. But survival rates have improved dramatically since 2011, with the advent of treatments such as immune checkpoint inhibitors and molecular therapy targeted for specific genetic mutuations. It’s now gratifying to be in a position improving upon an effective treatment designed for use when other effective treatments have failed, he said.
“It’s a disease that used to be a pariah,” said Kirkwood. “Now, it’s the poster child for all cancer. We have a trove of new treatments.”






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.